首页> 外文期刊>The Journal of arthroplasty >Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial
【24h】

Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial

机译:特立帕肽与阿仑膦酸盐用于全髋关节置换术后骨密度的保存-一项随机对照试验

获取原文
获取原文并翻译 | 示例
       

摘要

In this study, the effect of teriparatide for the prevention of bonemineral density (BMD) loss after THA was compared with alendronate in a randomized controlled trial. Forty-eight patients were assigned to three groups, namely, the teriparatide, alendronate, and no medication groups. Dual-energy x-ray absorptiometry (DEXA) was performed at 1 week post-surgery as a baseline reference, followed by subsequent measurements at 12, 24, and 48 weeks postoperatively. For periprosthetic BMD loss, a significant effect of teriparatide was demonstrated, though its effect was similar to alendronate. On the other hand, higher lumbar BMD was observed in the teriparatide group than in the alendronate group at 48 weeks post-surgery. Teriparatide administration may be one reasonable option for osteoporotic patient to preserve the periprosthetic BMD after THA. (C) 2016 Elsevier Inc. All rights reserved.
机译:在这项研究中,在一项随机对照试验中,比较了特立帕肽预防THA后预防骨矿物质密度(BMD)的作用与阿仑膦酸钠的作用。 48名患者被分为三组,即特立帕肽,阿仑膦酸盐和无药物治疗组。术后1周以双能X线骨密度仪(DEXA)作为基线参考,然后在术后12、24和48周进行后续测量。对于假体周围BMD的损失,特立帕肽具有明显的疗效,尽管其效果与阿仑膦酸盐相似。另一方面,在术后48周,特立帕肽组的腰椎BMD高于阿仑膦酸盐组。对于在THA后骨质疏松的患者保留假体周围的BMD,teriparatide给药可能是一种合理的选择。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号